04.09.13
Eddingpharm, a specialty pharma company in China, has entered into a collaboration agreement with GlaxoSmithKline China, to acquire exclusive rights in China to commercialize and distribute Tykerb, GSK’s treatment for advanced or metastatic breast cancer.
Tykerb, recently approved by the China State Food and Drug Administration (SFDA), is used in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy with an anthracycline, a taxane and trastuzumab.
Mr. Xin Ni, chairman and chief executive officer of Eddingpharm, said, "This cooperation with GSK on Tykerb is not only a milestone of Eddingpharm's business development history, but also an important milestone of China's pharmaceutical industry. This is the first time a Chinese pharmaceutical company will participate in the launch of a proprietary global oncology drug."
Tykerb, recently approved by the China State Food and Drug Administration (SFDA), is used in combination with capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy with an anthracycline, a taxane and trastuzumab.
Mr. Xin Ni, chairman and chief executive officer of Eddingpharm, said, "This cooperation with GSK on Tykerb is not only a milestone of Eddingpharm's business development history, but also an important milestone of China's pharmaceutical industry. This is the first time a Chinese pharmaceutical company will participate in the launch of a proprietary global oncology drug."